pediatric, prolonged released melatonin

Phase 3Small molecule

UUniversity Hospital, Strasbourg, France

pediatric, prolonged released melatonin is one of 45 small molecule programs targeting Post-Traumatic Stress Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Post-Traumatic Stress DisorderActive, not recruiting

Post-Traumatic Stress DisorderPhase 3

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Post-Traumatic Stress Disorder

#DrugCompanyPhaseTrials

Depakote

AbbVie

Phase 3

2 2

Maviret

AbbVie

Phase 3

1 3

Inderal

WWyeth-Lederle Vaccines

Phase 3

6 4

Depakote

Rexulti

3 6

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 7

Abilify

Otsuka

Phase 3

1 8

Duloxetine Hydrochloride

Eli Lilly

Phase 3

1 9

Keppra

UCB

Phase 2

1 10

Niacor

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Not yet recruiting

Post-Traumatic Stress Disorder

NCT07418554

Clinical

Trials by Indication[1]

Post-Traumatic Stress Disorder1 trial

Sleep Disturbances in Children and Adolescents With Post-traumatic Stress Disorder (PTSD): a Randomized Double-blind Placebo-controlled Trial to Investigate the Efficacy of Pediatric Prolonged-release Melatonin

Not yet recruiting·UUniversity Hospital, Strasbourg, France·Phase 3·NCT07418554·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for pediatric, prolonged released melatonin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pediatric, prolonged released melatonin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pediatric, prolonged released melatonin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Strasbourg, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Strasbourg, France

pediatric, prolonged released melatonin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Post-Traumatic Stress Disorder1 trial

References

Drug Info

Quick Facts

Related News